Della Chiesa Mariella, Setti Chiara, Giordano Chiara, Obino Valentina, Greppi Marco, Pesce Silvia, Marcenaro Emanuela, Rutigliani Mariangela, Provinciali Nicoletta, Paleari Laura, DeCensi Andrea, Sivori Simona, Carlomagno Simona
Department of Experimental Medicine (DIMES), University of Genoa, 16132 Genoa, Italy.
Pathology Unit, Galliera Hospital, 16128 Genoa, Italy.
Vaccines (Basel). 2022 Jun 28;10(7):1033. doi: 10.3390/vaccines10071033.
Human Natural Killer (NK) cells are all round players in immunity thanks to their powerful and immediate response against transformed cells and the ability to modulate the subsequent adaptive immune response. The potential of immunotherapies based on NK cell involvement has been initially revealed in the hematological setting but has inspired the design of different immune tools to also be applied against solid tumors, including colorectal cancer (CRC). Indeed, despite cancer prevention screening plans, surgery, and chemotherapy strategies, CRC is one of the most widespread cancers and with the highest mortality rate. Therefore, further efficient and complementary immune-based therapies are in urgent need. In this review, we gathered the most recent advances in NK cell-based immunotherapies aimed at fighting CRC, in particular, the use of monoclonal antibodies targeting tumor-associated antigens (TAAs), immune checkpoint blockade, and adoptive NK cell therapy, including NK cells modified with chimeric antigen receptor (CAR-NK).
人类自然杀伤（NK）细胞在免疫中是多面手，这得益于它们对转化细胞的强大而即时的反应以及调节后续适应性免疫反应的能力。基于NK细胞参与的免疫疗法的潜力最初在血液学领域得到揭示，但也激发了设计不同免疫工具以应用于包括结直肠癌（CRC）在内的实体瘤的灵感。事实上，尽管有癌症预防筛查计划、手术和化疗策略，但CRC仍是最常见的癌症之一，死亡率极高。因此，迫切需要进一步高效且互补的基于免疫的疗法。在本综述中，我们收集了旨在对抗CRC的基于NK细胞的免疫疗法的最新进展，特别是靶向肿瘤相关抗原（TAA）的单克隆抗体的使用、免疫检查点阻断以及过继性NK细胞疗法，包括用嵌合抗原受体修饰的NK细胞（CAR-NK）。
